ES2647618T3 - Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel - Google Patents

Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel Download PDF

Info

Publication number
ES2647618T3
ES2647618T3 ES12165557.5T ES12165557T ES2647618T3 ES 2647618 T3 ES2647618 T3 ES 2647618T3 ES 12165557 T ES12165557 T ES 12165557T ES 2647618 T3 ES2647618 T3 ES 2647618T3
Authority
ES
Spain
Prior art keywords
dermatitis
inflammatory skin
pharmaceutically acceptable
formulations
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES12165557.5T
Other languages
English (en)
Spanish (es)
Inventor
Jack A. Dejovin
Thomas M. Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Pharma SA
Original Assignee
Galderma Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/853,585 external-priority patent/US7439241B2/en
Application filed by Galderma Pharma SA filed Critical Galderma Pharma SA
Application granted granted Critical
Publication of ES2647618T3 publication Critical patent/ES2647618T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES12165557.5T 2004-05-25 2005-05-25 Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel Expired - Lifetime ES2647618T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57414204P 2004-05-25 2004-05-25
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
US853585 2004-05-25
US574142P 2004-05-25

Publications (1)

Publication Number Publication Date
ES2647618T3 true ES2647618T3 (es) 2017-12-22

Family

ID=35451386

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12165557.5T Expired - Lifetime ES2647618T3 (es) 2004-05-25 2005-05-25 Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel
ES05754754T Expired - Lifetime ES2424644T3 (es) 2004-05-25 2005-05-25 Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05754754T Expired - Lifetime ES2424644T3 (es) 2004-05-25 2005-05-25 Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel

Country Status (15)

Country Link
EP (2) EP1761266B1 (cg-RX-API-DMAC7.html)
JP (2) JP4955543B2 (cg-RX-API-DMAC7.html)
KR (1) KR101257046B1 (cg-RX-API-DMAC7.html)
CN (2) CN104490884A (cg-RX-API-DMAC7.html)
AU (1) AU2005247467B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0511519A (cg-RX-API-DMAC7.html)
CA (2) CA2824612C (cg-RX-API-DMAC7.html)
DK (1) DK1761266T3 (cg-RX-API-DMAC7.html)
ES (2) ES2647618T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA06013649A (cg-RX-API-DMAC7.html)
NZ (1) NZ552325A (cg-RX-API-DMAC7.html)
PL (1) PL1761266T3 (cg-RX-API-DMAC7.html)
PT (1) PT1761266E (cg-RX-API-DMAC7.html)
SI (1) SI1761266T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005115395A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
MX2012004890A (es) * 2009-10-26 2012-09-28 Galderma Pharma Sa Metodos para tratar o prevenir eritema agudo.
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CA2792649A1 (en) 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
KR20170018974A (ko) 2010-03-26 2017-02-20 갈데르마 리써어치 앤드 디벨로프먼트 홍반의 유효하고 안전한 치료를 위한 개선된 방법 및 조성물
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
JP2013540142A (ja) * 2010-10-21 2013-10-31 ガルデルマ・ソシエテ・アノニム 局所ゲル組成物
SG189896A1 (en) * 2010-10-21 2013-06-28 Galderma Sa Brimonidine gel compositions and methods of use
CN101972272B (zh) * 2010-10-31 2012-07-04 无锡龙腾画材有限公司 一种二氧化氯皮肤凝胶及其制备方法
CA2818144C (en) * 2010-11-16 2020-09-22 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
AU2012217858A1 (en) 2011-02-15 2013-09-05 Allergan, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
KR20140091543A (ko) * 2011-10-19 2014-07-21 갈데르마 소시에떼아노님 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
ES2765264T3 (es) * 2013-05-06 2020-06-08 Allergan Inc Agonistas alfa-adrenérgicos para el tratamiento de traumatismo tisular
WO2015013709A2 (en) * 2013-07-26 2015-01-29 Galderma Research & Development Method for treating skin thickening
CN110585173A (zh) 2013-10-07 2019-12-20 帝国制药美国公司 右旋美托咪啶经皮递送装置及其使用方法
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
WO2015054059A2 (en) 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US9937117B2 (en) 2015-07-09 2018-04-10 Galderma S.A. Method of reducing hair loss associated with chemotherapy
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
CN106727462B (zh) * 2016-11-14 2019-04-09 四川省人民医院 一种治疗面部皮炎的药物及其应用
SG11202106716RA (en) * 2019-01-12 2021-07-29 Cellix Bio Private Ltd Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
US20220218590A1 (en) * 2019-05-14 2022-07-14 Abend Fritz Ventures Llc Compositions and methods for removal of skin adhesive patches, products, and residual adhesives
CN116600785A (zh) * 2020-08-26 2023-08-15 奥蒂卡拉股份有限公司 用于治疗鼻、耳和其它组织感染和/或炎症的组合物、装置和方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
JPH1129482A (ja) * 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
CA2311344C (en) * 1997-11-24 2006-02-07 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
IN185228B (cg-RX-API-DMAC7.html) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
AU7326901A (en) * 2000-07-14 2002-01-30 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP3520076B2 (ja) * 2001-10-02 2004-04-19 憲司 中村 皮膚外用剤
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Also Published As

Publication number Publication date
EP2481412B1 (en) 2017-09-27
CN104490884A (zh) 2015-04-08
SI1761266T1 (sl) 2013-08-30
BRPI0511519A (pt) 2007-12-26
WO2005115395A2 (en) 2005-12-08
EP2481412A1 (en) 2012-08-01
CA2824612A1 (en) 2005-12-08
ES2424644T3 (es) 2013-10-07
EP1761266A4 (en) 2009-11-11
WO2005115395A3 (en) 2009-04-09
EP1761266A2 (en) 2007-03-14
JP2012072176A (ja) 2012-04-12
PT1761266E (pt) 2013-06-04
NZ552325A (en) 2010-11-26
CA2567401A1 (en) 2005-12-08
AU2005247467B2 (en) 2010-12-02
AU2005247467A1 (en) 2005-12-08
JP4955543B2 (ja) 2012-06-20
KR101257046B1 (ko) 2013-04-22
DK1761266T3 (da) 2013-08-05
EP1761266B1 (en) 2013-05-08
CA2567401C (en) 2013-11-12
KR20070032716A (ko) 2007-03-22
CN101426502A (zh) 2009-05-06
JP2008500356A (ja) 2008-01-10
PL1761266T3 (pl) 2013-09-30
MXPA06013649A (es) 2007-07-09
JP5547705B2 (ja) 2014-07-16
CA2824612C (en) 2016-08-16

Similar Documents

Publication Publication Date Title
ES2647618T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel
ES2547336T3 (es) Composición tópica para su uso para el tratamiento de enrojecimiento inducido por rosácea
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
Lin et al. A mind full of self: Self-referential processing as a mechanism underlying the therapeutic effects of mindfulness training on internalizing disorders
ES2532527T3 (es) Uso de agonistas del receptor adrenérgico alfa 2 para el tratamiento o prevención de la soriasis
HN2008001144A (es) Derivados de pirimidina utilizados como inhibidores de cinasa pi-3
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
BRPI0612072A2 (pt) inibidores da aspartil protease
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
CR9984A (es) Método de inhibición de cinasa de tirosina cinasa 3 similar a fms
BR112014000775A2 (pt) curativo de ferimento e método de tratamento
ECSP10010008A (es) (2s,3r)-n-(2-((3-piridinil)metil)-azabiciclo[2.2.2]oct-3- il)benzofuran-2-carboxamida, formas de sal novedosas, y métodos de uso de los mismos
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
WO2015054500A3 (en) Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
PH12015502275A1 (en) Therapuetic uses of empagliflozin
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
PE20131341A1 (es) Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
PE20211065A1 (es) Metodo para tratar la epilepsia
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.